Table 1.
Baseline characteristics
| n = 120 | |
|---|---|
| Age (years), median (IQR) | 55 (49–63) |
| Prostate volume (ml), median (IQR) | 35 (29–50) |
| Median lobe, n (%) No Yes |
88 (73.3) 32 (26.7) |
| ASA score, n (%) ASA I ASA II ASA III |
37 (30.8) 72 (60.0) 11 (9.2) |
| PSA (ng/ml), median (IQR) | 1.4 (0.7–2.2) |
| BPH medical therapy, n (%) No therapy Alpha-blocker Alpha-blocker + 5-ARI |
21 (17.5) 94 (78.3) 5 (4.2) |
| IPSS, median (IQR) | 21 (17–24) |
| IPSS-QoL, median (IQR) | 5 (4–5) |
| IIEF-5, median (IQR) | 19 (17–21) |
| Qmax (ml/s), median (IQR) | 9.8 (7.7–12.0) |
| PVR (ml), median (IQR) | 50 (23–100) |
ASA – American Society of Anesthesiologists; PSA – prostate-specific antigen; 5-ARI – 5-alpha reductase inhibitor; IPSS – International Prostate Symptoms Score questionnaire; IPSS-QoL – IPSS quality of life score; IIEF-5 – International Index of Erectile Function; Qmax – maximum flow rate; PVR – post-void residual